Boston Scientific Will Lean On Quadripolar, S-ICD To Revive Sagging U.S. CRM Sales
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific reported disappointing first-quarter results for its cardiac rhythm management division, mostly due to price erosion in the U.S and the lack of a quadripolar CRT-D device. But the firm argues that the new S-ICD and forthcoming quadripolar CRT-D products may help turn the business around soon.
You may also be interested in...
Boston Scientific Gets Early Nod For Next Gen S-ICD
Boston's Emblem S-ICD upgrade was approved by FDA and in Europe earlier than anticipated.
S-ICD Sales Exceeding Expectations, Boston Scientific Reports
The company said when S-ICD launched that it expected the device to be a major growth driver, and that appears to be working out so far. Boston Scientific now expects the leadless implantable defibrillator to bring in $100 million in revenue this year.
Boston Scientific Announces Six ICD/CRT-D Approvals
Boston Scientific announced FDA approval of the Dynagen Mini and Inogen Mini ICDs, which it claims are the thinnest and smallest ICDs available, and the Dynagen X4 and Inogen X4 quadripolar CRT-Ds.